Cancer/Testis Antigen Expression Panel Incorporating MAGEC1 and BAGE2 Predicts Multiple Myeloma Disease Stage and Severity

Simple item page
dc.contributor.authorShires, Karen
dc.contributor.authorTeuchert, Andrea
dc.contributor.authorWienand, Kirsty
dc.contributor.authorShankland, Iva
dc.contributor.authorNovitzky, Nicolas
dc.coverage.spatialSAen_ZA
dc.date.accessioned2016-11-09T13:45:28Z
dc.date.available2016-04-07
dc.date.available2016-11-09T13:45:28Z
dc.date.issued2016-04-07
dc.description.abstractTo provide a single molecular assay that could be used to easily stage Multiple Myeloma patients at diagnosis, we investigated the association between the simultaneous expression of 7 Multiple Myeloma-associated Cancer/Testis Antigens and biochemical parameters that are currently used for disease staging. We analysed the mRNA expression of MAGEC1, MAGEA3/A6, BAGE2, PRAME, NYESO1, SSX2 and PAGE by qualitative reverse transcription PCR using RNA extracted from diagnostic bone marrow samples from 39 patients covering the Multiple Myeloma disease continuum and compared this to levels of key biochemical parameters at diagnosis. We found that the Cancer/Testis Antigen panel was expressed in a specific order that was specifically associated with the severity of disease. This allowed the Cancer/Testis Antigens expression profile to successfully place the patient clearly into either stage I or stage III of the disease, with further sub-stratification in the stage III grouping. In addition, we putatively identified MAGEC1 expression as a confirmatory diagnostic marker for symptomatic Multiple Myeloma and clearly associated BAGE2 expression exclusively with stage III disease. We also demonstrated the novel finding of PAGE expression in Multiple Myeloma, with an association with more advanced disease. We suggest that this particular molecular Cancer/Testis Antigen panel can be used at diagnosis as a single test to clearly stage patientsen_ZA
dc.identifier.apacitationShires, K., Teuchert, A., Wienand, K., Shankland, I., & Novitzky, N. (2016). Cancer/Testis Antigen Expression Panel Incorporating MAGEC1 and BAGE2 Predicts Multiple Myeloma Disease Stage and Severity. <i>Journal of Hematology & Thromboembolic Diseases</i>, http://hdl.handle.net/11427/22457en_ZA
dc.identifier.chicagocitationShires, Karen, Andrea Teuchert, Kirsty Wienand, Iva Shankland, and Nicolas Novitzky "Cancer/Testis Antigen Expression Panel Incorporating MAGEC1 and BAGE2 Predicts Multiple Myeloma Disease Stage and Severity." <i>Journal of Hematology & Thromboembolic Diseases</i> (2016) http://hdl.handle.net/11427/22457en_ZA
dc.identifier.citationShires, K. and Wienand, K., 2016. Cancer testis antigen MAGE C1 can be used to monitor levels of circulating malignant stem cells in the peripheral blood of multiple myeloma patients. Journal of cancer research and clinical oncology, 142(11), pp.2383-2396. DOI: 10.4172/2329-8790.1000240en_ZA
dc.identifier.issn2329-8790en_ZA
dc.identifier.ris TY - Journal Article AU - Shires, Karen AU - Teuchert, Andrea AU - Wienand, Kirsty AU - Shankland, Iva AU - Novitzky, Nicolas AB - To provide a single molecular assay that could be used to easily stage Multiple Myeloma patients at diagnosis, we investigated the association between the simultaneous expression of 7 Multiple Myeloma-associated Cancer/Testis Antigens and biochemical parameters that are currently used for disease staging. We analysed the mRNA expression of MAGEC1, MAGEA3/A6, BAGE2, PRAME, NYESO1, SSX2 and PAGE by qualitative reverse transcription PCR using RNA extracted from diagnostic bone marrow samples from 39 patients covering the Multiple Myeloma disease continuum and compared this to levels of key biochemical parameters at diagnosis. We found that the Cancer/Testis Antigen panel was expressed in a specific order that was specifically associated with the severity of disease. This allowed the Cancer/Testis Antigens expression profile to successfully place the patient clearly into either stage I or stage III of the disease, with further sub-stratification in the stage III grouping. In addition, we putatively identified MAGEC1 expression as a confirmatory diagnostic marker for symptomatic Multiple Myeloma and clearly associated BAGE2 expression exclusively with stage III disease. We also demonstrated the novel finding of PAGE expression in Multiple Myeloma, with an association with more advanced disease. We suggest that this particular molecular Cancer/Testis Antigen panel can be used at diagnosis as a single test to clearly stage patients DA - 2016-04-07 DB - OpenUCT DP - University of Cape Town J1 - Journal of Hematology & Thromboembolic Diseases LK - https://open.uct.ac.za PB - University of Cape Town PY - 2016 SM - 2329-8790 T1 - Cancer/Testis Antigen Expression Panel Incorporating MAGEC1 and BAGE2 Predicts Multiple Myeloma Disease Stage and Severity TI - Cancer/Testis Antigen Expression Panel Incorporating MAGEC1 and BAGE2 Predicts Multiple Myeloma Disease Stage and Severity UR - http://hdl.handle.net/11427/22457 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/22457
dc.identifier.vancouvercitationShires K, Teuchert A, Wienand K, Shankland I, Novitzky N. Cancer/Testis Antigen Expression Panel Incorporating MAGEC1 and BAGE2 Predicts Multiple Myeloma Disease Stage and Severity. Journal of Hematology & Thromboembolic Diseases. 2016; http://hdl.handle.net/11427/22457.en_ZA
dc.languageengen_ZA
dc.publisherOMICS publishing groupen_ZA
dc.publisher.departmentDivision of Haematologyen_ZA
dc.publisher.facultyFaculty of Health Sciencesen_ZA
dc.publisher.institutionUniversity of Cape Town
dc.rightsCreative Commons Attribution 4.0 International (CC BY 4.0)*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_ZA
dc.sourceJournal of Hematology & Thromboembolic Diseasesen_ZA
dc.source.urihttp://www.esciencecentral.org/journals/haematology-thromboembolic-diseases.php
dc.titleCancer/Testis Antigen Expression Panel Incorporating MAGEC1 and BAGE2 Predicts Multiple Myeloma Disease Stage and Severityen_ZA
dc.typeJournal Articleen_ZA
uct.subject.keywordsBAGEen_ZA
uct.subject.keywordsStagingen_ZA
uct.subject.keywordsCascadeen_ZA
uct.subject.keywordsPrognosisen_ZA
uct.subject.keywordsMyelomaen_ZA
uct.type.filetypeText
uct.type.filetypeImage
uct.type.publicationResearchen_ZA
uct.type.resourceArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ShiresMultipleMyeloma.pdf
Size:
973.41 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.72 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Journal Articles